Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas

Leukemia

Volumn 14, Issue 3, 2000, Pages 446-448

  Bertoni, F ^a,c   Conconi, A ^a   Luminari, S ^b   Realini, C ^a   Roggero, E ^a   Baldini, L ^b   Carobbio, S ^a   Cavalli, F ^a   Neri, A ^b   Zucca, E ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

CD95; FAS; MALT; Marginal zone B cell lymphoma; Mutations

Indexed keywords

FAS ANTIGEN;

AMINO ACID SUBSTITUTION; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ELECTROPHORETIC MOBILITY; EXON; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; INTRON; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SILVER STAINING; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC MUTATION;

EID: 0034096184     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401708     Document Type: Article

References (30)

1. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11: 68-75.
2. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
3. Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 1997; 15: 417-474.
4. Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, Jackson CE, Puck JM, Dale J, Straus SE, Peter ME, Krammer PH, Fesik S, Lenardo MJ. Detective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. Proc Natl Acad Sci USA 1999; 96: 4552-4557.
5. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-1349.
6. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-946.
7. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KR. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 1999; 103: 355-363.
8. Zucca E, Roggero E, Pileri S. B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumours. Br J Haematol 1998; 100: 3-14.
9. Isaacson P. Gastric MALT lymphoma: from concept to cure. Ann Oncol 1999; 10: 637-645.
10. Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY, Yoo NJ. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 1999; 59: 3068-3072.
11. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, Park GS, Dong SM, Pi JH, Kim CS, Kim SH, Lee JY, Yoo NJ. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999; 18: 3754-3760.
12. Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY, Park JY, Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ, Lee SH. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 1999; 154: 1785-1791.
13. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K, Guldberg P. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998; 92: 3018-5024.
14. Beltinger C, Bohler T, Karawajew L, Ludwig WD, Schrappe M, Debatin KM. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 1998; 102: 722-728.
15. Tamiya S, Etoh K, Suzushima H, Takatsuki K, Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 1998; 91: 3935-3942.
16. Maeda T, Yamada Y, Moriuchi R, Sugahara K, Tsuruda K, Joh T, Atogami S, Tsukasaki K, Tomonaga M, Kamihira S. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 1999; 189: 1063-1071.
17. Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90: 4266-4270.
18. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
19. Bertoni F, Bosshard G, Roggero E, Ceresa E, Cavalli F, Zucca E. Clinical relevance of bcl-2 (MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. Br J Cancer 1997; 76: 36-39.
20. Benson DA, Boguski MS, Lipman DJ, Ostell J, Ouellette BF, Rapp BA, Wheeler DL. GenBank. Nucleic Acids Res 1999; 27: 12-17.
21. Fiucci G, Ruberti G. Detection of polymorphisms within the Fas cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis. Immunogenetics 1994; 39: 437-439.
22. Abdel-Rahman W, Arends M, Morris R, Ramadan M, Wyllie A. Death pathway genes fas (Apo-1/CD95) and bik (Nbk) show no mutations in colorectal carcinomas. Cell Death Differ 1999; 6: 387-388.
23. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128-135.
24. Bertolo F, De Vita S, Dolcetti R, Carbone A, Ferraccioli GF, Bartoli E, Boiocchi M. Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with Sjogren's syndrome and type II mixed cryoglobulinemia. Clin Exp Rheumatol 1999; 17: 339-342.
25. Peters AM, Kohfink B, Martin H, Griesinger F, Wormann B, Gahr M, Roesler J. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Exp Hematol 1999; 27: 868-874.
26. Haas JP, Grunke M, Frank C, Kolowos W, Dirnecker D, Leipold G, Hieronymus T, Lorenz HM, Herrmann M. Increased spontaneous in vitro apoptosis in double negative T cells of humans with a fas/apo-1 mutation. Cell Death Differ 1998; 5: 751-757.
27. Rieux-Laucat F, Blachere S, Danielan S, De Villartay JP, Oleastro M, Solary E, Bader-Meunier B, Arkwright P, Pondare C, Bernaudin F, Chapel H, Nielsen S, Berrah M, Fischer A. Deist FL. Lymphoproliferative syndrome with autoimmunily: a possible genetic basis for dominant expression of the clinical manifestations. Blood 1999; 94: 2575-2582.
28. Dierlamm J, Baens M, Wlodarska I. Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters C, Hagemeijer A, Van den Berghe H, Marynen P. The apoptosis inhibitor gene AP12 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93: 3601-3609.
29. Zhang Q, Siebert R, Van M, Hinzmann B, Cui X, Xue L, Rakestraw KM, Naeve CW, Beckmann G, Weisenburger DD, Sanger WG, Nowotny H, Vesely M, Callet-Bauchu E, Salles G, Dixit VM, Rosenthal A, Schlegelberger B, Morris SW. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999; 22: 63-68.
30. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson PG, Dyer MJ. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35-45.